Lamy Patrick 4
4 · Akero Therapeutics, Inc. · Filed Jun 20, 2025
Insider Transaction Report
Form 4
Lamy Patrick
Senior VP, Commercial Strategy
Transactions
- Sale
Common Stock
2025-06-16$53.82/sh−1,500$80,726→ 33,073 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-06-16−2,000→ 64,182 totalExercise: $19.87Exp: 2033-12-07→ Common Stock (83,182 underlying) - Exercise/Conversion
Common Stock
2025-06-16$19.87/sh+2,000$39,740→ 34,573 total - Sale
Common Stock
2025-06-16$55.09/sh−500$27,546→ 32,573 total
Footnotes (4)
- [F1]The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 6, 2025, previously adopted by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.52 to $54.37, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.70 to $55.57, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
- [F4]This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2023